Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. Clear all
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 9, 2026, 12:28 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).

NCT03790137
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Fenfluramine Hydrochloride
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
4 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 9, 2026, 12:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

NCT03936777
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
2 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 9, 2026, 12:28 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

NCT02682927
View directory record Official record
Conditions
Dravet Syndrome, Seizure Disorder
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 9, 2026, 12:28 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

NCT03467113
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome
Interventions
ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 9, 2026, 12:28 AM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 9, 2026, 12:28 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

NCT03299842
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 9, 2026, 12:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT03355209
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 9, 2026, 12:28 AM EDT